Table 1.

Published clinical series of pregnant NMOSD patients

Author	Year	Number of pregnancies	Number of patients	AQP4 antibody-positive patients	Results
Bourre et al. [56]	2012	25	20	8/19 (53%)a	Higher EDSS after pregnancy, no significant change in relapse rate during or following pregnancy
Kim et al. [29]	2012	54	40	40/40 (100%)	Increased relapse rate in the first 6 months after delivery; high relapse risk in patients not undergoing treatment; high rate of elective abortions; one premature birth in the third trimester with malformations
Fragoso et al. [53]	2013	17	17	n.a.	Higher EDSS after pregnancy; increased relapse rate in the first 3 months after delivery; no indications of malformation; diminished birth weight and length
Shimizu et al. [55]	2015	56	47	47/47 (100%)	Increased relapse rate in the first 3 months after delivery; AQP4 antibodies found in newborns, no longer detectable after 1 or 3 months, as applies
Nour et al. [54]	2016	126	60	60/60 (100%)	Increased relapse rate in the first 3 months after delivery; high rate of miscarriages (43%) for pregnancies after NMOSD onset, one child with hydrocephalus and permanent neurological disability
Klawiter et al. [52]	2017	46	31	25/31 (81%)	Increased relapse rate in the first trimester and in the first 3 months after delivery

EDSS Expanded Disability Status Scale, AQP4-Ak aquaporin4 antibodies, NMOSD neuromyelitis optica spectrum disorder, n.a. not applicable

^aAQP4-antibody serostatus only available for 19/20 patients